<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027468</url>
  </required_header>
  <id_info>
    <org_study_id>EK 548/2009</org_study_id>
    <nct_id>NCT01027468</nct_id>
  </id_info>
  <brief_title>Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration</brief_title>
  <official_title>Functional, Morphological And Safety Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration - 3 Years Of Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      200 eyes with each subtype of neovascular age-related macular degeneration will be included
      in this study and 3 years after the initial intravitreal bevacizumab, best-corrected visual
      acuity (BCVA) will be measured using Snellen charts at 6m. Central retinal thickness (CRT)
      will be measured using Stratus OCT and Cirrus SD-OCT (Zeiss). Data of treatment-naive eyes
      (group 1) were compared to the data of eyes that had undergone prior treatment with
      photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide (group 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this interventional clinical study, 181 eyes of 160 consecutive patients with active
      neovascular related macular degeneration meeting recommended criteria for inclusion and
      protocol criteria for anti-vascular endothelial growth factor therapy undergoing intravitreal
      bevacizumab monotherapy were evaluated. Data of treatment-naive eyes (Group 1, n = 114) were
      analyzed separately from eyes that had undergone previous photodynamic therapy plus
      intravitreal triamcinolone (Group 2, n = 67). Re-treatment criteria were based on clinical
      outcome following the official European label regimen. After 1 year of continuous service at
      an academic referral center, follow-up was performed in private practices in collaboration
      with the referral center. Main outcome parameters were best-corrected visual acuity and
      central retinal thickness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vision</measure>
    <time_frame>3 years after first intravitreal bevacizumab treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vision</measure>
    <time_frame>3 years after initial intravitreal bevacizumab treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic Complications After Treatment, Central Retinal Thickness</measure>
    <time_frame>3 years after initial bevacizumab treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>bevacizumab intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>intraocular bevacizumab injection</description>
    <arm_group_label>group 1</arm_group_label>
    <other_name>intraocular injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any subtype of neovascular age-related macular degeneration

          -  age of 50 years or older

          -  initial treatment with intravitreal bevacizumab between August 2005 and June 2006

        Exclusion Criteria:

          -  previous vitrectomy

          -  presence of cystoid macular edema without choroidal neovascularization

          -  Uncontrolled sytemic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Sacu, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Medical University of Vienna, Austria</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2009</study_first_submitted>
  <study_first_submitted_qc>December 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2009</study_first_posted>
  <results_first_submitted>January 7, 2014</results_first_submitted>
  <results_first_submitted_qc>January 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 20, 2014</results_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Stefan Sacu</investigator_full_name>
    <investigator_title>Assoc. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>bevacizumab, choroidal neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Medical University of Vienna, Department of Ophthalmology during September 2008-July 2009 with a mean of 3 year follow-up after initial Bevacizumab intravitreal treatment</recruitment_details>
      <pre_assignment_details>Inclusion criteria:
patients treated with bevacizumab due to wet age-related macular degeneration
follow-up of 3 years
Exclusion criteria:
- patients with other macular diseases</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>3 year follow-up of patients with intravitreal application of bevacizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>3 year follow-up of intravitreal application of bevacizumab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.24" spread="10.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Vision</title>
        <time_frame>3 years after first intravitreal bevacizumab treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>3 year follow-up of intravitreal application of bevacizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Vision</title>
          <units>logMar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vision</title>
        <time_frame>3 years after initial intravitreal bevacizumab treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Complications After Treatment, Central Retinal Thickness</title>
        <time_frame>3 years after initial bevacizumab treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>3 year follow-up of intravitreal application of bevacizumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>intraocular inflammation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Assoc.Prof.PD.Dr.Stefan Sacu</name_or_title>
      <organization>Medical University of Vienna</organization>
      <phone>+43404001 ext 7937</phone>
      <email>stefan.sacu@meduniwien.ac.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

